Vireo Growth (VREOF) Capital Expenditures Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.64 Bn | 87.78 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 22.98 Bn | 20.83 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | 28.56% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 279.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 279.36% |
| Dec 31, 2025 | 151.08% |
| Sep 30, 2025 | 137.41% |
| Jun 30, 2025 | 28.53% |
| Mar 31, 2025 | -20.31% |
| Dec 31, 2024 | -7.23% |
| Sep 30, 2024 | 10.63% |
| Jun 30, 2024 | -19.47% |
| Mar 31, 2024 | -43.26% |
| Dec 31, 2023 | -21.75% |
| Sep 30, 2023 | -58.83% |
| Jun 30, 2023 | 36.55% |
| Mar 31, 2023 | -26.89% |